ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2571

Anti-IL-6 Receptor Antibody Prevents Loss of Bone Strength in a Mouse Model of Collagen-Induced Arthritis

Hiroto Yoshida, Yuanyuan Bi, Miho Suzuki, Keisuke Tanaka and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Arthritis and mouse model, Bone, IL-6

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a disease that typically induces secondary osteoporosis, which increases the risk of bone fractures and, consequently, mortality. Bone fracture is induced not only by lower bone mineral density (BMD) but also by deterioration in bone structure. Anti-IL-6 receptor antibody is used as RA treatment, however its effect on bone strength is not clear. The purpose of this study is to clarify the influence of IL-6 on the changes of bone strength in arthritis, using a mouse model of collagen-induced arthritis (CIA). Additionally, we analyzed what correlates with bone strength in CIA mice.

Methods: CIA was immunized in DBA/1J mice by an intradermal injection of bovine type II collagen on Days 0 and 21. Mice were injected intraperitoneally with anti-mouse IL-6 receptor antibody (MR16-1) on Days 0 and 21. Urine and serum were sampled on Day 33-35. Urinary collagen type 1 cross-linked C-telopeptide (CTX), a bone resorption marker, and serum procollagen type 1 N-terminal propeptide (P1NP), a bone formation marker, were measured by ELISA. Femurs and feet were excised on Day 35, the peak of swelling of joints. As the bone structure, trabecular bone volume (BV/TV) of distal femur, and cortical bone thickness (Ct) of femur shaft, BMD of femur shaft and foot were analysed by micro-computed tomography (μCT). The bone strength of femur shaft was measured a maximum load by bending test.

Results: In CIA mice, urinary CTX and serum P1NP were significantly higher and lower, respectively, than in non-immunized mice. All parameters of bone structure (BV/TV of the distal femur, Ct of the femur shaft, BMD of the femur shaft and the foot) in CIA mice significantly decreased than in non-immunized mice. Moreover, maximum load of the femur shaft in CIA mice was significantly lower than in non-immunized mice. Maximum load of the femur shaft more strongly correlated with Ct of the femur shaft than BMD of the femur shaft and swelling score in hind limb. On the other hand, swelling score in the hind limb most strongly correlated with BMD of the foot, but did not correlate with Ct of the femur shaft. MR16-1 suppressed the development of arthritis. An increase in urinary CTX and a decrease in serum P1NP during development of CIA were suppressed by MR16-1. MR16-1 treatment significantly prevented a decrease in BV/TV of the distal femur, BMD of the foot and maximum load of the femur shaft by CIA induction.

Conclusion: We demonstrated that CIA induced loss of bone strength through a deterioration of bone structure and that cortical thickness has possibility of playing the most important role in bone strength. Moreover, our results indicated that IL-6 played an important role in bone strength because anti-IL-6 receptor antibody prevented the loss in bone strength in CIA.


Disclosure: H. Yoshida, None; Y. Bi, None; M. Suzuki, None; K. Tanaka, None; Y. Matsumoto, None.

To cite this abstract in AMA style:

Yoshida H, Bi Y, Suzuki M, Tanaka K, Matsumoto Y. Anti-IL-6 Receptor Antibody Prevents Loss of Bone Strength in a Mouse Model of Collagen-Induced Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/anti-il-6-receptor-antibody-prevents-loss-of-bone-strength-in-a-mouse-model-of-collagen-induced-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-il-6-receptor-antibody-prevents-loss-of-bone-strength-in-a-mouse-model-of-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology